<DOC>
	<DOC>NCT01894295</DOC>
	<brief_summary>The aim of this double blind clinical trial study is to investigate whether alphacalcidol treatment in obese subjects can affect the resting metabolic rate. Moreover, the investigators will evaluate the pathways of Nesfatin-1, Peroxisome proliferator-activated receptor gamma (PPARγ) and eroxisome proliferator-activated receptor- coactivator-1 α (PGC1α) protein which may lead to change in metabic rate following treatment with either alphacalcidol or placebo.</brief_summary>
	<brief_title>Assessment Vitamin D Analogues Intake Pathways on the Proteins Which Involved in Metabolic Rate in Obese Subjects</brief_title>
	<detailed_description />
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Hydroxycholecalciferols</mesh_term>
	<criteria>Age 2252 years Body mass index equal or more than 30 Acute or chronic inflammatory disease History of hypertension Alcohol or drug abuse History of any condition affecting inflammatory markers Thyroid diseases Malignancies Current smoking Diabetes mellitus Sustained hypertension Heart failure Acute or chronic infections Hepatic or renal diseases Use of PPARγ agonist drug</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>52 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Vitamin D analogues</keyword>
	<keyword>Resting Metabolic rate</keyword>
	<keyword>obesity</keyword>
</DOC>